动态心电图监测变异型心绞痛发作

例1 患者男,71岁,因背部压迫样不适伴胸前区压榨性疼痛半年,加剧1周就诊。心电图检查正常。X线胸片诊断为2、3胸椎骨折。考虑胸前区压榨性疼痛属胸椎骨折所致的放射性疼痛。经骨科治疗后,因病人胸痛未缓解,2天后     

头颈部肿瘤放疗不良反应的护理

放射治疗是当前治疗头颈部恶性肿瘤的重要手段之一。放疗后肿瘤患者生存率和生存时间提高。而放疗又给患者带来不良反应及并发症。头颈部肿瘤患者在放疗中严重的并发症是:口腔溃疡、咽干、咽痛、皮肤脱屑(放射性皮炎)甚至破溃形成溃疡。其次是消化道反应。均可影响病人治疗,或使治疗终止,对病人预后及生存率有较大影响。     

十二指肠破裂憩室化改良术二例

十二指肠破裂是腹部外伤中较严重的急症，我们用十二指肠憩室化改良法成功地治愈2例，操作要点如下：修补十二指肠破裂伤口，丝线环幽门浆肌层缝合一周，收紧缝线，关闭幽门。针距间外露缝线处水平褥式浆肌层缝合包埋。做结肠前胃空肠吻合，输入袢与输出袢间加做Braun吻合。腔外缝闭输入袢“入口处”，即输入袢与胃吻合处。从输入袢向十二指肠腔插入一减压性造接瘘流管。此改良法具备十二指肠憩室化标准法的一切优点，作用等同，较之简易安全。十二指肠破裂憩室化改良术二例@赵长远$辽宁省新民市人民医院!110300@石茂兴$辽宁省新民市人民医…     

微量电鳐乙酰胆碱酯酶抑制法测定低剂量梭曼浓度

微量电鳐乙酰胆碱酯酶抑制法测定低剂量梭曼浓度刘星，陈起展梭曼是一种能对机体内乙酰胆碱酯酶（ＡＣｈＥ）强烈抑制而产生毒性的有机磷化合物。我们在Ｈａｍ－ｍｏｎｄ［１］等建立的微量ＡＣｈＥ抑制法测定微量有机磷毒剂浓度基础上改进，建立了一种新型的测定方法，其...     

脾形态的应用解剖学观察

本文对经10％甲醛固定的正常成人50例脾进行了观察测量,结果如下:1.脾外形可分三型:三角形(52％±7.0％),椭圆形(44％±7.09％),圆形(4％±2.8％)。2.脾的测量:脾长10.06±1.80cm,脾宽7.03±1.36cm,脾厚3.27±0.74cm。3.脾切迹:脾前缘有1个切迹的18％±5.49％,2个切迹的30％±6.55％,3个切迹的36％±6.86％,4个切迹的6％±3.39％,5个切迹的6％±3.39％。4.副脾:出现率8％。     

电子知情同意系统在临床应用中的挑战及改进建议

电子知情同意系统是电子化、智能化技术现代化发展的产物,在疫情防控背景下,它能够适应疫情防控的要求,具有跨时空优势。通过介绍电子知情同意系统的概念、呈现形式和使用情况等内容,分析电子知情同意系统所面临的接受度、理解、同意和信息安全等方面所面临的挑战。在此基础上提出应加强电子知情同意系统相关人员的培训,加强和完善电子知情同意系统的功能以及完善电子知情同意系统的相关法律法规等建议,以期为未来电子知情同意的研究和应用提供参考。     

治疗脑中风的抗氧化剂/自由基清除剂类药物

介绍目前临床使用或正在开发的、治疗脑中风的抗氧化剂／自由基清除剂类神经元保护剂。脑中风是造成中老年人致死、致残的主要疾病。氧自由基是造成脑损伤的主要因素之一，自由基清除剂能最大限度地保护脑组织，降低中风的危险。神经元保护剂的使用可延长最佳治疗时间，已成为目前治疗脑中风的主要方法。     

中西医结合治疗溃汤性结肠炎48例

本组48例患者，其中，男33例。女15例；年龄最小17岁，最大76岁。每日腹泻次数大于10次者30例，伴便血者7例。     

注射用重组改构人肿瘤坏死因子联合化疗治疗晚期恶性肿瘤的临床观察

Objective: Past studies showed that tumor necrosis factor (TNF) assisted anti-tumor treatment and intensified the sensitivity of chemotherapy. However its clinical application has been curbed because of its low purity, high dosage, and strong toxicity. The objective of present study is to evaluate the therapeutic effects and adverse reactions of recombinant mutant human tumor necrosis factor (rmhTNF) combined with chemotherapy in patients with advanced malignant tumor. Methods: 105 patients with advanced malignant tumor were randomly divided into trial group, 69 patients, and control group, 36 patients. rmhTNF was injected intramuscularly to the trial group at a dose of 4×10⁶ U/m², from the 1st to 7th days, the 11th to 17th days combined with chemotherapy course. The chemotherapy plan was as follows: CAP for patients with the NSCLC; FAM for patients with gastric cancer; FC for patients with colorectal cancer. One treatment cycle lasted for 21 days and two cycles were scheduled. The control group was given only the same chemotherapy as the trial group. Results: In the trial group there was 1 CR case and 12 PR cases, and the response rate was 13/69 (18.84%); in the control group 1 PR case, the response rate 1/36 (2.78%). The response rate in the trial group was significantly higher than that in the control group (P=0.022). The response rate for NSCLC in the trial group was 8/17 (47.06%), and 1/6 (16.67%) in the control group. The response rates for gastric cancer and colorectal cancer in the trial groups also were higher than those in the control groups. After the treatment the KPS was 89.00±9.92 in the trial group, and 84.17±8.84 in the control group, with a significant difference between the two groups (P=0.028). The adverse reactions of rmhTNF injection included: pain in the injection area, chill, hardening and swelling and redness in the injection area, fever, ostealgia and myosalgia, and cold-like symptoms. All these adverse reactions were mild and bearable. Conclusion: The administration of rmhTNF in combination with general chemotherapy is an effective and secure means in treating advanced malignant tumor.